Results 251 to 260 of about 368,793 (264)

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

Annals of Oncology, 2019
Eduardo Vilar, S Kopetz, Christine Parseghian   +2 more
exaly  

Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

Cancer Cell, 2019
Raúl Rabadan, TERESA Blasco, Francisca Mulero   +2 more
exaly  

EGFR

2017
openaire   +1 more source

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ca-A Cancer Journal for Clinicians
Kaushal Parikh, Jair Bar, Claudio De Vito   +2 more
exaly  

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Annals of Oncology, 2014
Gregory Riely, M D Hellmann, G J Riely   +2 more
exaly  

Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach

Ca-A Cancer Journal for Clinicians
Jyoti Malhotra, Lauren Antrim
exaly  

Targeting the EGFR signaling pathway in cancer therapy

Expert Opinion on Therapeutic Targets, 2012
Moorthy Palanimuthu Ponnusamy, Surinder K Batra, Maneesh Jain   +2 more
exaly  

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Journal of Thoracic Oncology, 2015
Shaodong Hong, Shiyang Kang, Jianhua Zhan   +2 more
exaly  

Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification

Ca-A Cancer Journal for Clinicians
Gilberto de Lima Lopes
exaly  

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Nature Reviews Clinical Oncology, 2009
Antonella De Luca, Fortunato Ciardiello, Eric Van Cutsem   +2 more
exaly